MYOact GmbH

MYOact GmbH specializes in the myoact EMG Biofeedbacktraining system, a device that uses electromyography (EMG) technology to analyze muscle function. It helps users identify muscle imbalances and supports the design of targeted training or therapeutic programs by providing real-time feedback. The system is tailored for applications where muscle function assessment and biofeedback are critical.

MYOact GmbH is headquartered in Germany, which places its devices under the regulatory framework of the European Union. Since the myoact EMG Biofeedbacktraining system is classified as a Class I medical device, it is subject to EU requirements for conformity assessment and registration. The company lists its devices in the eudamed database, which is the EU’s official registry for medical devices, ensuring transparency and compliance with EU regulations.

MYOact GmbH’s myoact EMG Biofeedbacktraining system is registered in the eudamed database, the EU’s central registry for medical devices. Listing in eudamed is mandatory for Class I devices under EU Medical Device Regulation (MDR) or Medical Device Directive (MDD) to demonstrate compliance, traceability, and market surveillance. This registry helps healthcare professionals, regulators, and authorities verify the device’s legal status and manufacturer details.

The myoact EMG Biofeedbacktraining system is classified as a Class I medical device, which is the lowest risk category under EU regulations. This classification means the device poses minimal risk to patients or users and typically requires only basic conformity assessment procedures, such as self-certification by the manufacturer. For users, this classification indicates that the device has undergone necessary safety and performance evaluations to ensure it can be used reliably for EMG biofeedback training without high-risk complications.